Diazepam

證據等級: L5

預測適應症: 10 個

Diazepam: Drug Repurposing Evaluation — Pending TxGNN Predictions

One-Sentence Summary

Diazepam is a well-established benzodiazepine agent widely used clinically for its anxiolytic, anticonvulsant, muscle-relaxant, and sedative properties. This Evidence Pack contains no TxGNN-predicted new indications, and critical data fields — including mechanism of action, safety warnings, and contraindications — remain unpopulated. A complete repurposing evaluation cannot be performed until the outstanding data gaps identified in this pack are resolved.

Quick Overview

Item	Content
Original Indication	Not available in this Evidence Pack
Predicted New Indication	No predictions available
TxGNN Prediction Score	N/A
Evidence Level	N/A — predictions absent
New Zealand Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack (Data Gap DG002). Based on general pharmacological knowledge, Diazepam is a benzodiazepine that enhances GABAergic inhibition via positive allosteric modulation of GABA-A receptors, producing central nervous system depression. This broad mechanism has historically attracted research interest in areas beyond its core indications, including neuroprotection, alcohol withdrawal, and palliative symptom management.

However, because the TxGNN prediction pipeline has not yet generated repurposing candidates for this drug, it is not possible to assess mechanistic applicability to any specific new therapeutic area at this time. All reasoning in this section remains speculative until predictions are available.

Clinical Trial Evidence

Currently no related clinical trials registered for TxGNN-predicted repurposing indications.

Literature Evidence

Currently no related literature available for TxGNN-predicted repurposing indications.

New Zealand Market Information

The Medsafe database query returned 0 authorizations for Diazepam as of 2026-04-20.

Note: This result warrants manual verification. Diazepam is a widely distributed generic medicine included on the WHO Essential Medicines List; a null result may reflect a query scope limitation rather than a true absence of New Zealand market authorization. A direct search of the Medsafe consent database is recommended before drawing conclusions.

Safety Considerations

Please refer to the package insert for safety information.

Both key warnings (DG001 — Blocking severity) and contraindications are currently unavailable in this Evidence Pack. The TFDA package insert PDF has been queried successfully (query_log ID 4, status: success) but parsed data has not been populated into the safety fields. This must be resolved before any clinical evaluation proceeds.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN predicted indications array is empty and all critical safety fields are unpopulated; no meaningful repurposing signal can be evaluated from the current Evidence Pack, making any go/no-go recommendation premature.

To proceed, the following is needed:

[Priority 1 — Blocking] Parse the TFDA package insert PDF (query success confirmed) and populate safety warnings and contraindications fields (DG001)
[Priority 2 — High] Query DrugBank API to retrieve mechanism of action data for Diazepam (DG002)
[Priority 3] Execute the TxGNN prediction pipeline for Diazepam to generate ranked repurposing candidates with scores and evidence linkages
[Priority 4] Manually verify New Zealand Medsafe authorization status — the 0-license result is inconsistent with Diazepam's global availability profile
[Priority 5] Re-run DDI query once drug identity confirmation and pipeline alignment are complete
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.